NUBEQA is currently indicated for the treatment of adult patients with mHSPC in combination with docetaxel and for non-metastatic castration-resistant prostate cancer (nmCRPC)
Teliso-V is an investigational antibody-drug conjugate (ADC) for patients with previously treated nonsquamous non-small cell lung cancer (NSCLC) with c-Met protein overexpression
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
This validation aligns with Piramal Pharma's core purpose of 'Doing Well and Doing Good,'
The wP-IPV-based hexavalent vaccination is an innovative immunization alternative to the current pentavalent and standalone IPV vaccines
MedTech Mitra initiative aims to empower MedTech innovators and advance healthcare solutions
H.coagulans is, unlike other general lactobacillus, characterized by spore formation, giving it resistance to acid and heat
Strong topline growth driven by solid performance across key brands.
The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
The drug will be marketed in different strengths of 150 mg and 440 mg and used in the treatment of patients with HER2
Subscribe To Our Newsletter & Stay Updated
